31 Uveal Melanoma

Uveal Melanoma

19

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/04/2020

21. Dieckmann K, Georg D, Zehetmayer M, Bogner J, Georgopoulos M, Pötter R. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol. 2003;67(2):199–206. doi:10.1016/s0167- 8140(02)00345-6 22. Dieckmann K, Georg D, Zehetmayer M, Rottenfusser A, Pötter R. Stereotactic photon beam irradiation of uveal melanoma: indications and experience at the University of Vienna since 1997. Strahlenther Onkol. 2007;183 Spec No 2:11–13. doi:10.1007/s00066-007-2005-6 23. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119(7):969–982. doi:10.1001/ archopht.119.7.969 24. Echegaray JJ, Bechrakis NE, Singh N, Bellerive C, Singh AD. Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of RadiationDose. Ocul Oncol Pathol. 2017;3(3):193–198. doi:10.1159/000455872 25. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55(4):867– 880. doi:10.1016/s0360-3016(02)04200-1 26. Finger PT, Chin KJ, Tena LB. A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve. Ophthalmology. 2012;119(2):415–422. doi:10.1016/j.ophtha.2011.08.017 27. Finger PT, Lu D, Buffa A, DeBlasio DS, Bosworth JL. Palladium-103 versus iodine-125 for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys. 1993;27(4):849–854. doi:10.1016/0360-3016(93)90459-9 28. Finger PT, Reddy S, Chin K. High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy. Arch Ophthalmol. 2007;125(8):1051–1058. doi:10.1001/archopht.125.8.1051 29. Finger PT. Intraocular melanoma. In: DeVita JVT, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncol-ogy. 10th ed. Philadelphia, Pennsylvania, USA: Wolter Kluwer, Lippincott, Williams and Wilkins; 2014. p. 1770–9. 30. Fontanesi J, Meyer D, Xu S, Tai D. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys. 1993;26(4):619–623. doi:10.1016/0360- 3016(93)90278-4 31. Gagne NL, Cutright DR, Rivard MJ. Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity. J Contemp Brachytherapy. 2012;4(3):165–175. doi:10.5114/jcb.2012.30683 32. Gaspar de Souza Neves DF, Ferragut MA, Ferreira DV, et al. Reirradiation of the eye with plaque brachytherapy: a single institution experience report of eight consecutive patients submitted to retreatment after local relapse of malignant disease of the eye. Brachytherapy. 2014;13(3):281–284. doi:10.1016/j. brachy.2013.10.007 33. Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond). 2013;27(2):163–171. doi:10.1038/ eye.2012.249 34. Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999;117(5):609–614. doi:10.1001/archopht.117.5.609 35. Heilemann G, Fetty L, Blaickner M, et al. Retina dose as a predictor for visual acuity loss in 106Ru eye plaque brachytherapy of uveal melanomas. Radiother Oncol. 2018;127(3):379–384. doi:10.1016/j.radonc.2017.11.010 36. Heilemann G, Fetty L, Dulovits M, et al. Treatment plan optimization and robustness of 106Ru eye plaque brachytherapy using a novel software tool. Radiother Oncol. 2017;123(1):119–124. doi:10.1016/j.radonc.2017.01.010 37. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19 [published correction appears in Ophthalmology. 2004 Aug;111(8):1514]. Ophthalmology. 2002;109(12):2197–2206. doi:10.1016/s0161-6420(02)01277-0 38. Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63(2):93–102. doi:10.4103/0301-4738.154367 39. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241–257. doi:10.1038/eye.2016.275

40. King B, Morales-Tirado VM, WynnHG, Gao BT, BalloMT, WilsonMW. Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma. Am J Ophthalmol. 2017;176:40–45. doi:10.1016/j.ajo.2016.12.022 41. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–4659. doi:10.1167/iovs.03-0538 42. Le BHA, Kim JW, Deng H, et al. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review. Brachytherapy. 2018;17(6):981–989. doi:10.1016/j.brachy.2018.07.002 43. Liu W, Kim JM, Young BK, et al. Novel Eye Plaque Designs for Brachytherapy of Iris and Ciliary Body Melanoma and the First Clinical Application. Ocul Oncol Pathol. 2019;5(3):220–227. doi:10.1159/000493269 44. Lommatzsch PK. Opthalmologische Onkologie. 1999 Enke, Stuttgart. 45. Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years’ experience. Br J Ophthalmol. 1986;70(11):844–851. doi:10.1136/bjo.70.11.844 46. Luxton G, Astrahan MA, Liggett PE, Neblett DL, Cohen DM, Petrovich Z. Dosimetric calculations and measurements of gold plaque ophthalmic irradiators using iridium-192 and iodine-125 seeds. Int J Radiat Oncol Biol Phys. 1988;15(1):167–176. doi:10.1016/0360-3016(88)90362-8 47. Marinkovic M, Horeweg N, Fiocco M, et al. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. Eur J Cancer. 2016;68:106–113. doi:10.1016/j. ejca.2016.09.009 48. MartinD et al ClinOcul Oncol 1989 Churchill Livingstone, 2nd edition, NewYork. 49. Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–366. doi:10.1016/s0161-6420(00)00526-1 50. Nag S, Quivey JM, Earle JD, et al. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2):544–555. doi:10.1016/s0360-3016(03)00006-3 51. Naseripour M, Jaberi R, Sedaghat A, et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy. 2016;8(1):66–73. doi:10.5114/jcb.2016.57818 52. Nathan P, Cohen V, Coupland S, et al. Uveal Melanoma UK National Guidelines. Eur J Cancer. 2015;51(16):2404–2412. doi:10.1016/j.ejca.2015.07.013 53. Ophthalmic Oncology Task Force. Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma. Ophthalmology. 2 0 1 6 ; 1 2 3 ( 1 ) : 8 6 – 9 1 . d oi : 1 0 . 1 0 1 6 / j. op ht h a . 2 0 1 5 . 0 9 . 0 1 4 54. Perri P, Fiorica F, D’Angelo S, et al. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience. Eur Rev Med Pharmacol Sci. 2012;16(14):1919–1924. 55. Poder J, Corde S. I-125 ROPES eye plaque dosimetry: validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculationsoftwarewithGafChromic®EBT3films.MedPhys.2013;40(12):121709. doi:10.1118/1.4828786 56. Quivey JM, Augsburger J, Snelling L, Brady LW. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer. 1996;77(11):2356–2362. doi:10.1002/(SICI)1097- 0142(19960601)77:11<2356::AID-CNCR26>3.0.CO;2-V 57. Razzaq L, Keunen JE, Schalij-Delfos NE, Creutzberg CL, Ketelaars M, de Keizer RJ. Rutheniumplaque radiation therapy for iris and iridociliarymelanomas. Acta Ophthalmol. 2012;90(3):291–296. doi:10.1111/j.1755-3768.2010.01967.x 58. Reichstein D, Karan K. Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. Curr Opin Ophthalmol. 2018;29(3):191–198. doi:10.1097/ICU.0000000000000468 59. Rivard MJ, Chiu-Tsao ST, Finger PT, et al. Comparison of dose calculation methods for brachytherapy of intraocular tumors. Med Phys. 2011;38(1):306–316. doi:10.1118/1.3523614